The 9th International Congress on Peritoneal Surface Malignancies, sponsored by the Peritoneal Surface Oncology Group International （PSOGI） and organized by the Netherlands Cancer Institute, was held in Amsterdam, t...The 9th International Congress on Peritoneal Surface Malignancies, sponsored by the Peritoneal Surface Oncology Group International （PSOGI） and organized by the Netherlands Cancer Institute, was held in Amsterdam, the Netherlands, from October 9 to 11, 2014, with over 650 delegates from 66 countries attending the meeting. With the central theme to summarize the global progresses in peritoneal carcinomatosis （PC） diagnosis and treatment, to draft the outline framework of international guidelines on PC treatment, and to formulate the future international collaborative research programs, this congress has set the new historical milestones in the global joint-effort to conquer PC. Major highlights of this congress are reported here.展开更多
In this editorial we examine the article by Wu et al published in the World Journal of Gastrointestinal Oncology.Surgical resection for peritoneal metastases from colorectal cancer(CRC)has been gradually accepted in t...In this editorial we examine the article by Wu et al published in the World Journal of Gastrointestinal Oncology.Surgical resection for peritoneal metastases from colorectal cancer(CRC)has been gradually accepted in the medical oncology community.A randomized trial(PRODIGE 7)on cytoreductive surgery(CRS)with hyperthermic intraperitoneal chemotherapy(HIPEC)failed to prove any benefit of oxaliplatin in the overall survival of patients with peritoneal metastases from colorectal origin.Nevertheless,isolated systemic chemotherapy for CRC stage IV has demonstrated a reduced response in peritoneal metastases than that obtained in other metastatic sites such as the liver.Another tool is required in those patients to achieve more local control of the disease.Surgical groups in peritoneal surgery continue to use HIPEC in their procedures,using other agents than oxaliplatin for peritoneal cavity infusion,such as mitomycin C.These patients present with complex surgical issues to manage,and consequently a large burden of complications has to be anticipated.Therefore,identifying patients who will benefit from CRS with or without HIPEC would be of great interest.展开更多
文摘The 9th International Congress on Peritoneal Surface Malignancies, sponsored by the Peritoneal Surface Oncology Group International （PSOGI） and organized by the Netherlands Cancer Institute, was held in Amsterdam, the Netherlands, from October 9 to 11, 2014, with over 650 delegates from 66 countries attending the meeting. With the central theme to summarize the global progresses in peritoneal carcinomatosis （PC） diagnosis and treatment, to draft the outline framework of international guidelines on PC treatment, and to formulate the future international collaborative research programs, this congress has set the new historical milestones in the global joint-effort to conquer PC. Major highlights of this congress are reported here.
文摘In this editorial we examine the article by Wu et al published in the World Journal of Gastrointestinal Oncology.Surgical resection for peritoneal metastases from colorectal cancer(CRC)has been gradually accepted in the medical oncology community.A randomized trial(PRODIGE 7)on cytoreductive surgery(CRS)with hyperthermic intraperitoneal chemotherapy(HIPEC)failed to prove any benefit of oxaliplatin in the overall survival of patients with peritoneal metastases from colorectal origin.Nevertheless,isolated systemic chemotherapy for CRC stage IV has demonstrated a reduced response in peritoneal metastases than that obtained in other metastatic sites such as the liver.Another tool is required in those patients to achieve more local control of the disease.Surgical groups in peritoneal surgery continue to use HIPEC in their procedures,using other agents than oxaliplatin for peritoneal cavity infusion,such as mitomycin C.These patients present with complex surgical issues to manage,and consequently a large burden of complications has to be anticipated.Therefore,identifying patients who will benefit from CRS with or without HIPEC would be of great interest.
